CD40LG and primary biliary cholangitis: In contrast, in 20 Japanese PBC patients followed for a mean duration of 13.5 years, 5 patients received UDCA therapy, the AMA titers did not significantly change over time regardless of UDCA therapy (12), and UDCA was found to reduce the IgM-AMA but not IgG-AMA levels in peripheral blood mononuclear cells from Japanese PBC patients after bacterial CpG challenge (13).